weight loss

Deal Discussions Distract From Disappointing Obesity Drug Sales (video)

Deal Discussions Distract From Disappointing Obesity Drug Sales (video)

Motley Fool

Why Does Arena's Obesity Drug Have Abuse Potential?

Why Does Arena's Obesity Drug Have Abuse Potential?

Forbes

Exciting Catalysts Approaching for This Bet

Exciting Catalysts Approaching for This Bet

Motley Fool

An Obesity Drugmaker's Critical Coming Weeks

An Obesity Drugmaker's Critical Coming Weeks

Motley Fool

How Doctors Actually Diagnose Obesity

How Doctors Actually Diagnose Obesity

Motley Fool

The Obesity Drug War Continues

The Obesity Drug War Continues

Motley Fool

First Manhattan seeks seats on Vivus board as diet drug founders

First Manhattan seeks seats on Vivus board as diet drug founders

Reuters

A Drug That's Ready to Lose

A Drug That's Ready to Lose

Motley Fool

KYTHERA Biopharmaceuticals, Inc. to Present New Data at 2013 American Academy of Dermatology (AAD) Annual Meeting Demonstrating Results for ATX-101 in the Reduction of Submental Fat (SMF) or “Double Chin”

KYTHERA Biopharmaceuticals, Inc. to Present New Data at 2013 American Academy of Dermatology (AAD) Annual Meeting Demonstrating Results for ATX-101 in the Reduction of Submental Fat (SMF) or “Double Chin”

Yahoo/BusinessWire

Will There Ever Be an Obesity Drug Blockbuster?

Will There Ever Be an Obesity Drug Blockbuster?

Motley Fool